Table 2 Multivariate logistic regression analysis for predictors of complete treatment within 1 year after beginning anti-tuberculosis (TB) treatment
Number | Completion rate | Unadjusted OR (95% CI) | P-value | Adjusted OR (95% CI) | P-value | |
|---|---|---|---|---|---|---|
Implementation of DOTS | ||||||
Pre-DOTS era (2004–2005) | 28,913 | 68.9% | 1 | 1 | ||
DOTS era (2006–2009) | 52,168 | 72.5% | 1.19 (1.16, 1.23) | <0.001 | 1.25 (1.21, 1.30) | <0.001 |
Age (years) | <0.001 | |||||
20–34 | 9595 | 85.0% | 1 | 1 | ||
35–49 | 13,319 | 79.1% | 0.67 (0.63, 0.72) | <0.001 | 0.84 (0.78, 0.91) | <0.001 |
50–64 | 17,347 | 75.3% | 0.54 (0.51, 0.58) | <0.001 | 0.81 (0.75, 0.87) | <0.001 |
65–79 | 26,897 | 68.3% | 0.38 (0.36, 0.41) | <0.001 | 0.69 (0.64, 0.74) | <0.001 |
80 and above | 13,923 | 54.8% | 0.21 (0.20, 0.23) | <0.001 | 0.43 (0.40, 0.46) | <0.001 |
Sex | ||||||
Female | 24,914 | 71.7% | 1 | 1 | ||
Male | 56,167 | 71.0% | 0.97 (0.93, 1.00) | 0.033 | 1.15 (1.11, 1.19) | <0.001 |
Comorbidities | ||||||
No | 47,182 | 78.3% | 1 | |||
Any | 33,899 | 61.4% | 0.44 (0.43, 0.45) | <0.001 | ||
Diabetes mellitus | ||||||
No | 58,079 | 73.2% | 1 | 1 | ||
Yes | 23,002 | 66.3% | 0.72 (0.70, 0.75) | <0.001 | 0.93 (0.89, 0.96) | <0.001 |
Chronic obstructive pulmonary disease | ||||||
No | 74,449 | 73.2% | 1 | 1 | ||
Yes | 6632 | 48.8% | 0.35 (0.33, 0.37) | <0.001 | 0.53 (0.50, 0.56) | <0.001 |
Malignancy | ||||||
No | 74,017 | 73.5% | 1 | 1 | ||
Yes | 7064 | 47.3% | 0.32 (0.31, 0.34) | <0.001 | 0.38 (0.36, 0.41) | <0.001 |
End-stage renal disease | ||||||
No | 79,172 | 71.9% | 1 | 1 | ||
Yes | 1909 | 42.9% | 0.29 (0.27, 0.32) | <0.001 | 0.41 (0.37, 0.45) | <0.001 |
Liver cirrhosis | ||||||
No | 80,631 | 71.5% | 1 | 1 | ||
Yes | 450 | 31.1% | 0.18 (0.15, 0.22) | <0.001 | 0.21 (0.17, 0.27) | <0.001 |
Autoimmune disease | ||||||
No | 80,262 | 71.4% | 1 | 1 | ||
Yes | 819 | 59.6% | 0.59 (0.51, 0.68) | <0.001 | 0.69 (0.59, 0.81) | <0.001 |
Acquired immunodeficiency syndrome | ||||||
No | 80,632 | 71.3% | 1 | 1 | ||
Yes | 449 | 53.9% | 0.47 (0.39, 0.57) | <0.001 | 0.37 (0.30, 0.45) | <0.001 |
Low income | ||||||
No | 78,213 | 71.4% | 1 | 1 | ||
Yes | 2868 | 66.5% | 0.80 (0.73, 0.86) | <0.001 | 0.86 (0.79, 0.95) | 0.002 |
Hospital accreditation levels of initial visits | ||||||
Medical centers or regional hospitals | 43,360 | 67.0% | 1 | |||
Local hospitals or clinics | 37,721 | 76.1% | 1.57 (1.52, 1.62) | <0.001 | 1.25 (1.20, 1.30) | <0.001 |
Specialties of initial visits | ||||||
Pulmonologists or infection specialists | 14,102 | 72.5% | 1 | 1 | ||
Others | 66,979 | 71.0% | 0.93 (0.89, 0.97) | <0.001 | 0.83 (0.79, 0.87) | <0.001 |
Hospitalisation within 14 days of commencing anti-TB treatment | ||||||
No | 38,809 | 82.0% | 1 | 1 | ||
Yes | 42,272 | 61.3% | 0.35 (0.34, 0.36) | <0.001 | 0.62 (0.60, 0.64) | <0.001 |
Requiring intensive care within 14 days of commencing anti-TB treatment | ||||||
No | 72,565 | 75.8% | 1 | 1 | ||
Yes | 8516 | 32.6% | 0.16 (0.15, 0.16) | <0.001 | 0.54 (0.50, 0.59) | <0.001 |
Invasive ventilatory support within 14 days of commencing anti-TB treatment | ||||||
No | 73,333 | 75.7% | 1 | 1 | ||
Yes | 7748 | 28.8% | 0.13 (0.12, 0.14) | <0.001 | 0.39 (0.36, 0.42) | <0.001 |
Non-invasive ventilatory support within 14 days of commencing anti-TB treatment | ||||||
No | 79,780 | 71.9% | 1 | 1 | ||
Yes | 1301 | 30.9% | 0.18 (0.16, 0.20) | <0.001 | 0.75 (0.66, 0.86) | <0.001 |
Second-line anti-TB treatment ≥14 days | ||||||
No | 67,190 | 76.9% | 1 | 1 | ||
Yes | 13,891 | 44.0% | 0.24 (0.23, 0.25) | <0.001 | 0.29 (0.28, 0.31) | <0.001 |
Delay in anti-TB treatment (per week) | 0.992 (0.990, 0.994) | <0.001 | ||||